Clinical Scorecard: UTICalc 3.0 Shows Promise for UTI Risk

At a Glance

Key Highlights

• UTICalc 3.0 demonstrated strong accuracy in predicting UTIs with an AUROC of 84% for the clinical model and 95% for the clinical and dipstick model.
• At the 5% risk threshold, the clinical model had 82% sensitivity and 74% specificity.
• The clinical and dipstick model achieved 94% sensitivity and 87% specificity at the 5% threshold.
• Decision curve analysis indicated a positive net benefit for both models across various thresholds.
• Physicians' clinical judgment remains essential despite the utility of UTICalc models.

Guideline-Based Recommendations

Diagnosis

• Use clinical and dipstick models to assess UTI risk in febrile pediatric patients.

Management

• Consider urine testing based on UTICalc recommendations, particularly for patients at higher risk.

Monitoring & Follow-up

• Follow up on urine test results and clinical outcomes to ensure accurate diagnosis.

Risks

• Potential for missed UTIs due to incomplete follow-up and reliance on caregiver-reported information.

Patient & Prescribing Data

Febrile pediatric patients aged 2 to 24 months.

UTICalc models can guide urine testing decisions but should not replace clinical judgment.

Clinical Best Practices

• Utilize UTICalc models as a supplementary tool for decision-making in UTI risk assessment.
• Maintain a high index of suspicion for UTIs in febrile infants, especially those under 12 months.

References

• JAMA Network Open